1
|
Lunguț EF, Antal C, Turcu S, Varlas VN, Filipescu AG, Balescu I, Bacalbașa N, Gorecki GP. Neurasites ®-A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks. J Clin Med 2024; 13:3364. [PMID: 38929892 PMCID: PMC11203885 DOI: 10.3390/jcm13123364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2024] [Revised: 06/03/2024] [Accepted: 06/05/2024] [Indexed: 06/28/2024] Open
Abstract
Background/Objectives: Migraine is one of the most common diseases in highly developed countries, being even more common than diabetes and asthma. Migraines can affect emotional, social, and physical wellbeing as well as professional life. The most common symptoms are severe headaches associated with nausea, vomiting, photophobia and sonophobia, difficulty concentrating, sensitivity and emotional disorders. Many studies have been published to establish the best migraine-management drugs, but not many of them refer to plant extracts, which have been given more attention by patients lately. Among these generically called herbal medicines, the effect of tussilago hybrida standardized extract has been studied since the early twenties. This stands as the fundamental component of Neurasites® and the reason for research on materials and methods, results on treatment schemes for diminishing migraine attack features, as well as migraine prevention. Methods: There are two directions of research (herbal and placebo medicine) considered to be of interest due to the actual trend toward natural medicine and against chemicals and associated drugs. For quantitative research, the research tool used was that of the Neurasites® Questionnaire Survey (NQS). Results: The obtained results prove the efficacy of treatment by reducing the duration of headache attacks, diminishing pain intensity and decreasing the frequency of migraine episodes. Conclusions: Further research development should focus on other dosages and treatment schemes and on other similar natural products to be used in migraine attack treatment.
Collapse
Affiliation(s)
- Emilia Furdu Lunguț
- Department of Neurology, Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania;
- Department of Neurology, CF2 Clinical Hospital, 011464 Bucharest, Romania
| | - Claudia Antal
- 2gether NHS Foundation Trust for Gloucestershire, Gloucestershire GL3 4AW, UK;
| | - Suzana Turcu
- Romanian Academy, “Francisc I. Rainer” Institute of Anthropology, 050711 Bucharest, Romania;
| | - Valentin-Nicolae Varlas
- Department of Obstetrics and Gynecology, “Carol Davila” University of Medicine, 050474 Bucharest, Romania; (V.-N.V.); (A.G.F.)
- Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011132 Bucharest, Romania
| | - Alexandru George Filipescu
- Department of Obstetrics and Gynecology, “Carol Davila” University of Medicine, 050474 Bucharest, Romania; (V.-N.V.); (A.G.F.)
- Department of Obstetrics and Gynecology, Elias Emergency Clinical Hospital, 011461 Bucharest, Romania
| | - Irina Balescu
- Department of General Surgery, “Carol Davila” University of Medicine, 050474 Bucharest, Romania;
| | - Nicolae Bacalbașa
- Department of Visceral Surgery, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Visceral Surgery, Center of Excellence in Translational Medicine “Fundeni” Clinical Institute, 022328 Bucharest, Romania
- Department of Visceral Surgery, Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Gabriel-Petre Gorecki
- Department of Anesthesia and Intensive Care, “Titu Maiorescu” University, Faculty of Medicine, 031593 Bucharest, Romania;
- Department of Anesthesia and Intensive Care, CF2 Clinical Hospital, 011464 Bucharest, Romania
| |
Collapse
|
2
|
Dighriri IM, Nazel S, Alharthi AM, Altowairqi NA, Albariqi AM, Tohari MA, Alameer AA, Alsaran AK, ALshammari FR, AlMutairi NF, Alsubaie FM, Alharbi TA. A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine. Cureus 2023; 15:e48160. [PMID: 38046695 PMCID: PMC10693258 DOI: 10.7759/cureus.48160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/02/2023] [Indexed: 12/05/2023] Open
Abstract
Ubrogepant is an innovative medication designed for the acute treatment of migraine, a debilitating neurological condition that profoundly impairs quality of life, productivity, and social interactions. This comprehensive review assesses the efficacy, safety, tolerability, and mechanism of action of ubrogepant through a rigorous methodology, including an in-depth literature review from reputable databases like PubMed, Web of Science, Embase, Scopus, and Cochrane. Classified as a calcitonin gene-related peptide (CGRP) receptor antagonist, ubrogepant has emerged as a potential revolutionary medication for migraine treatment. CGRP is a peptide integral to migraine pathophysiology, and its blockade has demonstrated great therapeutic potential. Unlike triptans, known for their cardiovascular risks, ubrogepant lacks vasoconstrictive properties, making it a safer alternative for a broader patient population. Ubrogepant offers significant potential for pain relief, symptom reduction, and restoration of normal function during a migraine attack, and it outperforms placebo in terms of efficacy. It also presents favorable safety, with generally mild adverse drug events (ADEs), such as nausea, dizziness, and somnolence, similar to placebo effects. Consistent results from clinical trials confirm its tolerability, with minor ADEs and no safety alerts for the tested doses, indicating that ubrogepant is a safe and well-tolerated option for migraine treatment. As an effective oral medication, ubrogepant could be an alternative to traditional acute migraine treatments. Its benefits include a unique mechanism of action, rapid onset, and favorable safety profile. However, specific contraindications, such as hypersensitivity, severe hepatic impairment, concurrent use of CYP3A4 inhibitors, pregnancy or breastfeeding, and uncontrolled hypertension, require caution or avoidance of ubrogepant. Despite these limitations, ubrogepant signals a promising new direction in migraine therapeutics.
Collapse
Affiliation(s)
| | - Shahad Nazel
- Faculty of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, SAU
| | | | | | - Aqeel M Albariqi
- Department of Pharmacy, Bariq Primary Health Care Center, Bariq, SAU
| | - Mona A Tohari
- Department of Pharmacy, Alhada Armed Forces Hospital, Taif, SAU
| | | | - Amjad K Alsaran
- Department of Pharmacy, Specialized Medical Center Hospital, Riyadh, SAU
| | | | - Naif F AlMutairi
- Department of Pharmacy, Maternity and Children Hospital, Buraydah, SAU
| | - Fahad M Alsubaie
- Department of Pharmacy, King Abdulaziz Specialist Hospital, Taif, SAU
| | - Turki A Alharbi
- Department of Pharmacy, Al Rass General Hospital, Al Rass, SAU
| |
Collapse
|